Brokerages forecast that Opko Health Inc. (NASDAQ:OPK) will report sales of $307.44 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Opko Health’s earnings, with the highest sales estimate coming in at $325.20 million and the lowest estimate coming in at $296.51 million. Opko Health reported sales of $275.50 million during the same quarter last year, which indicates a positive year-over-year growth rate of 11.6%. The business is scheduled to report its next earnings results on Wednesday, March 7th.
According to Zacks, analysts expect that Opko Health will report full year sales of $307.44 million for the current financial year, with estimates ranging from $1.17 billion to $1.20 billion. For the next year, analysts expect that the business will report sales of $1.29 billion per share, with estimates ranging from $1.26 billion to $1.34 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Opko Health.
Several research analysts recently commented on the stock. Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. Cantor Fitzgerald set a $20.00 target price on shares of Opko Health and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Finally, BidaskClub downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 11th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $13.34.
A number of large investors have recently added to or reduced their stakes in the stock. Alliancebernstein L.P. boosted its holdings in shares of Opko Health by 18.6% during the 2nd quarter. Alliancebernstein L.P. now owns 213,324 shares of the biotechnology company’s stock valued at $1,404,000 after buying an additional 33,400 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Opko Health by 1.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 53,788 shares of the biotechnology company’s stock valued at $354,000 after buying an additional 896 shares in the last quarter. UBS Asset Management Americas Inc. boosted its holdings in shares of Opko Health by 8.5% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 224,668 shares of the biotechnology company’s stock valued at $1,478,000 after buying an additional 17,541 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Opko Health by 1.1% during the 2nd quarter. Vanguard Group Inc. now owns 26,618,758 shares of the biotechnology company’s stock valued at $175,151,000 after buying an additional 296,757 shares in the last quarter. Finally, California Public Employees Retirement System boosted its holdings in shares of Opko Health by 2.2% during the 2nd quarter. California Public Employees Retirement System now owns 779,356 shares of the biotechnology company’s stock valued at $5,128,000 after buying an additional 16,900 shares in the last quarter. Institutional investors and hedge funds own 22.22% of the company’s stock.
Opko Health (OPK) traded down $0.11 during mid-day trading on Friday, hitting $3.85. 2,463,500 shares of the company’s stock traded hands, compared to its average volume of 4,748,437. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.48. Opko Health has a 52-week low of $3.61 and a 52-week high of $8.92. The stock has a market capitalization of $2,150.00, a P/E ratio of -20.26 and a beta of 1.42.
ILLEGAL ACTIVITY WARNING: “Analysts Expect Opko Health Inc. (OPK) Will Post Quarterly Sales of $307.44 Million” was originally reported by Week Herald and is the property of of Week Herald. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://weekherald.com/2018/03/14/analysts-expect-opko-health-inc-opk-will-post-quarterly-sales-of-307-44-million.html.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.